Disease phenotype analyses of relapsing-remitting multiple sclerosis in Canada and Saudi Arabia
Mohammad Alluqmani(University of Alberta), P. D. Christopher(Alberta Hospital Edmonton), Gregg Blevins, M Alqermli(Fundación Medina), Batool Alotibi(Fundación Medina), Fabrizio Giuliani(University of Alberta)
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
May 1, 2015
Cited by 0
Related Papers
Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation
|Nature Medicine|2007|1.8k
The Role of Inflammation in Depression and Fatigue
|Frontiers in Immunology|2019|651
The promise of minocycline in neurology
|The Lancet Neurology|2004|521
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
|The Lancet Neurology|2018|345
Interleukin‐1β promotes oligodendrocyte death through glutamate excitotoxicity
|Annals of Neurology|2003|257